| 1. |
|
|
| 2. |
- Gizaw, NY, et al.
(författare)
-
PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targets
- 2022
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 1091-6490. ; 119:49, s. e2116220119-
-
Tidskriftsartikel (refereegranskat)abstract
- Rhabdomyosarcoma (RMS) is an aggressive pediatric soft-tissue cancer with features of skeletal muscle. Because of poor survival of RMS patients and severe long-term side effects of RMS therapies, alternative RMS therapies are urgently needed. Here we show that the prospero-related homeobox 1 (PROX1) transcription factor is highly expressed in RMS tumors regardless of their cell type of origin. We demonstrate that PROX1 is needed for RMS cell clonogenicity, growth and tumor formation. PROX1 gene silencing repressed several myogenic and tumorigenic transcripts and transformed the RD cell transcriptome to resemble that of benign mesenchymal stem cells. Importantly, we found that fibroblast growth factor receptors (FGFR) mediated the growth effects of PROX1 in RMS. Because of receptor cross-compensation, paralog-specific FGFR inhibition did not mimic the effects of PROX1 silencing, whereas a pan-FGFR inhibitor ablated RMS cell proliferation and induced apoptosis. Our findings uncover the critical role of PROX1 in RMS and offer insights into the mechanisms that regulate RMS development and growth. As FGFR inhibitors have already been tested in clinical phase I/II trials in other cancer types, our findings provide an alternative option for RMS treatment.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Bohling, N, et al.
(författare)
-
Notes on the Cretan mistletoe, Viscum album subsp creticum subsp nova (Loranthaceae/Viscaceae)
- 2002
-
Ingår i: Israel journal of plant sciences. - 0792-9978. ; 50:Suppl 1, s. 77-84
-
Konferensbidrag (refereegranskat)abstract
- Viscum album subsp. creticum, known from two mountain areas of E. Crete, is described as new to science. It combines features of the two presently accepted conifer mistletoes, resembling the fir parasite, subsp. abietis, in gross morphology but genetically (by nrDNA ITS sequence data) close to the pine parasite, subsp. austriacum, while differing from either in hypocotyl shape and nucleotide sequences of cpDNA. Its host is Pinus halepensis subsp. brutia, a taxon not normally affected by mistletoes. It is thus likely that the new subspecies has its own, particular host tree. Hypotheses of the Cretan mistletoe's history and endemic status are discussed on the background of documented size fluctuations of Cretan pine forests and their propensity to burning.
|
|
| 6. |
- Ferrari, S, et al.
(författare)
-
Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups
- 2005
-
Ingår i: Journal of Clinical Oncology. - 1527-7755. ; 23:34, s. 8845-8852
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose To explore the effect of high-dose ifosfamide in first-line treatment for patients <= 40 years of age with nonmetastatic osteosarcoma of the extremity. Patients and Methods From March 1997 to September 2000, 182 patients were evaluated. Primary treatment consisted of two blocks of high-dose ifosfamide (15 g/m(2)), methotrexate (12 g/m(2)), cisplatin (120 mg/m(2)), and doxorubicin (75 mg/m(2)). Postoperatively, patients received two cycles of doxorubicin (go mg/m(2)), and three cycles each of high-dose ifosfamide, methotrexate, and cisplatin (120 to 150 mg/m(2)). Granulocyte colony-stimulating factor support was mandatory after the high-dose ifosfamide/cisplatin/doxorubicin combination. Results No disease progression was recorded during primary chemotherapy, 164 patients (92%) underwent limb-salvage surgery, four patients (2%) underwent rotation plasty, and 11 patients (6%) had limbs amputated. Three (1.6%) patients died as a result of treatment-related toxicity, and one died as a result of pulmonary embolism after pathologic fracture. Grade 4 neutropenia and thrombocytopenia followed 52% and 31% of all courses, respectively, and mild to severe nephrotoxicity was recorded in 19 patients (10%). The median received dose-intensity compared with protocol was 0.82. With a median follow-up of 55 months, the 5-year probability of event-free survival was 64% (95% CI 57% to 71%) and overall survival was 77% (95% CI 67% to 81%), whereas seven patients (4%) experienced local recurrence. Conclusion The addition of high-dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosfamide. Italian Sarcoma Group/Scandinavian Sarcoma Group study I showed that in a multicenter setting, more than 90% of patients with osteosarcoma of the extremity can undergo conservative surgery.
|
|
| 7. |
|
|
| 8. |
- Kontio, R, et al.
(författare)
-
Craniomaxillofacial osteosarcoma - The role of surgical margins
- 2019
-
Ingår i: Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. - : Elsevier BV. - 1878-4119. ; 47:6, s. 922-925
-
Tidskriftsartikel (refereegranskat)
|
|
| 9. |
|
|
| 10. |
|
|
